Alnylam Pharmaceuticals (ALNY) Earnings Projection: Strong 2025 Net Product Revenue Between $2.05B and $2.25B

Alnylam Pharmaceuticals on Smartkarma

Analysts on Smartkarma are bullish on Alnylam Pharmaceuticals, with reports from Baptista Research highlighting the company’s strong financial performance and strategic growth. In one report titled “Alnylam Pharmaceuticals: Pipeline Expansion In Neurodegenerative Diseases As A Pivotal Factor Driving Growth! – Major Drivers,” it is noted that Alnylam demonstrated significant growth in Q3 2024, with a 34% year-over-year increase in global net product revenue. The success is largely attributed to the performance of its TTR franchise, generating $309 million, up by 34% from the previous year.

Similarly, in another report titled “Alnylam Pharmaceuticals: Launch & Uptake of Vutrisiran & Other Major Drivers,” Baptista Research underscores Alnylam’s robust performance in the second quarter of 2024, with a 34% year-over-year increase in global net product revenues totaling $410 million. The growth was primarily driven by a 37% increase in the hereditary ATTR amyloidosis (hATTR) franchise. As a result, the company raised its revenue guidance for the year, reflecting confidence in its future prospects.

A look at Alnylam Pharmaceuticals Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Alnylam Pharmaceuticals Inc., an early-stage therapeutics company, shows a promising long-term outlook according to Smartkarma Smart Scores. With a strong emphasis on Growth and Resilience, scoring 4 and 5 respectively, the company’s future prospects appear bright. Their focus on developing technology to silence disease-causing genes positions them well for sustained growth in the biopharmaceutical industry.

Although Alnylam Pharmaceuticals scores lower in Value and Dividend, with scores of 2 and 1 respectively, their high marks in Growth and Resilience indicate a solid foundation for long-term success. Momentum also plays a role in their outlook, scoring a respectable 3. Investors looking for a company with potential for significant growth may find Alnylam Pharmaceuticals a compelling choice, given its strong emphasis on innovation and addressing unmet medical needs.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma